Juventas’ innovation is stemmed from its integrated R&D platforms including CAR and gene-editing technologies. With more than 10 drug candidates in its pipeline, featured with solo, dual, or multiple target autologous CAR-T and universal cellular products, Juventas is well on its way to fulfil its mission - providing novel solutions to unmet clinical needs in the treatment of blood cancers, solid tumors, and other diseases. Beside self-driven innovation, Juventas is open for domestic and international collaborations, and has developed close partnership cooperation with China national top scientific institutes and clinical research centers, to diligently translate frontier science and technology advancement into bedside therapies/treatments.
| Platform |
Indication |
Products |
Preclinical
Studies |
Exploratory
Clinical
Trials |
IND |
Clinical Trial for Registration
Phase I
Phase II
|
NDA |
Hematologic
Tumors |
Acute Lymphoblastic
Leukemia (ALL) |
HY001 (CNCT19） |
|
|
|
|
|
|
Acute Lymphoblastic
Leukemia (ALL) |
HY004 |
|
|
|
|
|
|
Non-Hodgkin
Lymphoma (NHL) |
HY001（CNCT19） |
|
|
|
|
|
|
Non-Hodgkin
Lymphoma (NHL) |
HY012 |
|
|
|
|
|
|
Non-Hodgkin
Lymphoma (NHL) |
HY003 |
|
|
|
|
|
|
Multiple Myeloma
(MM) |
HY015 |
|
|
|
|
|
|
Acute Myeloid
Leukemia (AML) |
HY007 |
|
|
|
|
|
|
| Solid Tumors |
Malignant
Melanoma, etc. |
HY024 |
|
|
|
|
|
|
Non-Small Cell Lung
Cancer, etc. |
Multi-Product |
|
|
|
|
|
|
Universal
and Allograft |
Multiple indications |
Innate immune cell
platform |
|
|
|
|
|
|
| Multiple indications |
Gene editing
platforms |
|
|
|
|
|
|
+86-010-65960020
pr@juventas.cn
查看更多 +